Strikingly, the screened compounds WS6, ispinesib, ponatinib and cabozantinib displayed a lower IC50 than the FDA-approved compounds for FLT3-ITD+ AML (Figure S2A,B). The gene discussed is FLT3; the disease is acute myeloid leukemia.